Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILCC trial in recurrent, metastatic, or persistent cervical cancer
jRCTc031200283Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes and aldesleukin in Cervical Cancer (CC), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Best overall response rate and Adverse events. Started Oct 2021; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytesaldesleukin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCTc031200283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTc031200283.